Cipla
Search results
Download Complete Annual Report. Managing Director’s Message and Management Discussion & Analysis. Board’s Report and Corporate Governance. Business Responsibility and Sustainability Report. Standalone Financial Results. Consolidated Financial Results.
As per SMSRC data for February 2022, Sun Pharma ranks No. 1 by prescriptions with 11 different classes of doctors. We continued our new launches momentum with 77 new
Sun Pharmaceutical Industries Limited ANNUAL REPORT 2022-23 Reaching People. Touching Lives.
Sun Pharma is ranked No. 1 and holds 8.3% market share in the over Rs. 1,688 Billion Indian pharmaceutical market as per AIOCD AWACS MAT March-2022 report. For Q4FY22, the company launched 11 new products in the Indian market. US Formulations (including Taro)
Mumbai, May 26, 2023: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) reported financials for the fourth quarter and full year ending March 31, 2023. Highlights of FY23 consolidated financials. Gross sales at Rs. 432,789 million, growth of 12.6% over same period last year .
Investor Presentation – January 2024. At Sun, we remain committed to creating long term value for our shareholders. In line with this philosophy, we will continue to focus on performance and producing consistent returns.
Sun Pharmaceutical Industries Ltd. Annual Reports: Review of financial performance, strategy, and achievements.
Get a detailed Sensex annual report of Sun Pharmaceutical Industries on stock/share exchange market for the financial 2021 and more at Moneycontrol.com.
submitting herewith the Annual Report including the Business Responsibility Report of the Company for the financial year 2020-21 alongwith the Notice of the 29th Annual General Meeting of the Company, scheduled to be held on Tuesday, August 31, 2021 at 03.00 p.m.
Sun Pharmaceutical Industries Detailed director reports covering Sun Pharma Financial Results and Performance report.
